Pyxis Oncology, Inc. /
Apexigen, Inc.
Pyxis Oncology adds Apexigen in an all-stock transaction
What happened
Pyxis Oncology, Inc. completed its acquisition of Apexigen, Inc. in an all-stock transaction valued at approximately $10.7 million. Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology.
The combination adds an antibody-discovery platform, a Phase 2 candidate and a royalty stream.
The source
Everything on this page comes from the source below.
Pyxis Oncology adds Apexigen in an all-stock transaction
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly